An AI-Driven Approach to CHO Biologics Production

• Demonstrating an integrated AI and synthetic biology platform that routinely achieves high clonal titers across antibody formats, from mAbs to complex multispecifics.
• Overview of Asimov’s Rapid Pools platform, which generates high-throughput stable CHO expression pools to provide early, CLD-relevant expression and product quality data for better decision making.
• Case studies spanning vector design, cell line development, and protein engineering showing how computational methods reduce empirical iteration and accelerate manufacturing readiness.

Speakers:

Raja Srinivas

Co-Founder

Asimov